| Literature DB >> 35215300 |
Mario A Tan1, Niti Sharma2, Seong Soo A An2.
Abstract
Neurodegenerative diseases (NDs) mainly affect neurons and gradually lead to a loss of normal motor and cognitive functions. Atypical protein homeostasis-misfolding, aggregations and accumulations, oxidative stress, inflammation, and apoptosis-are common features in most NDs. To date, due to the complex etiology and pathogenesis of NDs, no defined treatment is available. There has been increasing interest in plant extracts as potential alternative medicines as the presence of various active components may exert synergistic and multi-pharmacological effects. Murraya koenigii (Rutaceae) is utilized in Ayurvedic medicine for various ailments. Pharmacological studies evidenced its potential antioxidant, anti-inflammatory, anticancer, hepatoprotective, immunomodulatory, antimicrobial, and neuroprotective activities, among others. In line with our interest in exploring natural agents for the treatment of neurodegenerative diseases, this review presents an overview of literature concerning the mechanisms of action and the safety profile of significant bioactive components present in M. koenigii leaves to support further investigations into their neuroprotective therapeutic potential.Entities:
Keywords: Murraya koenigii; carbazole alkaloids; essential oils; natural products; neurodegenerative disease; toxicity
Year: 2022 PMID: 35215300 PMCID: PMC8880493 DOI: 10.3390/ph15020188
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Mechanism of action of different extracts of Murraya koeingii leaves and their bioactive components in ameliorating symptoms of NDs.
| Extract/Bioactive Components | Model | Property | Neuroprotective Mechanism | Refs. |
|---|---|---|---|---|
| Alkaloid extract | Swiss Albino aged mice (in vivo) | Antioxidant properties | Reduced LPO, NO, | [ |
| Aqueous extract | Aluminum-treated rats | Antioxidant properties | Decreased LPO, | [ |
| Aqueous extract | Paraquat-induced Parkinsonism in rats | Antioxidant properties | Better performance in behavioral and locomotor activities, | [ |
| β-Caryophyllene | Brain of patients (Postmortum) | Agonist of CB2R | Activation of CB2R, | [ |
| (+)-3-Carene | In vitro | Enzyme inhibition | Uncompetitive inhibitor of AChE | [ |
| Caryophyllene oxide | In vitro, in silico | Enzyme inhibition | Inhibitor of AChE | [ |
| Geranyl acetate | In vitro, in silico | Enzyme inhibition | Inhibitor of AChE | [ |
| Isolongifolene | SH-SY5Y (in vitro) | Antioxidant properties | Downregulated the expression of Bax, caspases-3, 6, 8, and 9, cytosolic cyt c; increased Bcl-2 expression, | [ |
| Leaf powder | Diazepam-, scopolamine- and ageing-induced amnesia behavioral models in rats (in vivo) | Nootropic effect | Improved memory and learning impairment, | [ |
| Linalool | Aβ1-42-treated rats | Antioxidant properties | Cognitive-enhancing effects, | [ |
| Mahanimbine | SK-N-SH (in vitro) | Antioxidant properties, Anti-inflammatory | Inhibited BACE1 and AChE, | [ |
| Methanolic extract | Two-vessel occlusion rat model of partial global cerebral ischemia (in vivo) | Nootropic effect | Improved memory and learning impairment | [ |
| β-Myrcene | Global cerebral ischemia/reperfusion (I/R) in C57BL/J6 mice | Antioxidant properties | Protection against oxidative stress, apoptosis, and histopathological damage | [ |
| Nerolidol | Rotenone-induced model of PD (in vivo) | Antioxidant properties, Anti-inflammatory | Increased SOD, CAT, GSH, | [ |
| Spathulenol | SH-SY5Y (in vitro) | Antioxidant properties | Maintained mitochondrial membrane integrity | [ |
Figure 1Biologically active natural products from Murraya koenigii against neurodegenerative diseases.
Figure 2Mechanisms of action of the identified bioactive compounds from Murraya koenigii.